Abstract
Although hepatocyte growth factor (HGF) can act synergistically or antagonistically with transforming growth factor-β (TGF-β) signaling, molecular mechanism of their crosstalk remains unknown. Using antibodies which selectively distinguished receptor-regulated Smads (R-Smads) phosphorylated at linker regions from those at C-terminal regions, we herein showed that either HGF or TGF-β treatment of normal stomach-origin cells activated the JNK pathway, thereafter inducing endogenous R-Smads phosphorylation at linker regions. However, the phosphorylation at their C-terminal regions was not induced by HGF treatment. The activated JNK could directly phosphorylate R-Smads in vitro at the same sites that were phosphorylated in response to TGF-β or HGF in vivo. Thus, the linker regions of R-Smads were the common phosphorylation sites for HGF and TGF-β signaling pathways. The phosphorylation induced by simultaneous treatment with HGF and TGF-β allowed R-Smads to associate with Smad4 and to translocate into the nucleus. JNK pathway involved HGF and TGF-β-mediated infiltration potency since a JNK inhibitor SP600125 caused the reduction of invasive capacity induced by HGF and TGF-β signals. Moreover, a combined treatment with HGF and TGF-β led to a potent increase in plasminogen activator inhibitor type 1 transcriptional activity through Smad3 phosphorylation at the linker region. In contrast, HGF treatment reduced TGF-β-dependent activation of p15INK4B promoter, in which Smad3 phosphorylation at the C-terminal region was involved. In conclusion, HGF and TGF-β transmit the signals through JNK-mediated R-Smads phosphorylation at linker regions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- ERK:
-
extracellular signal-regulated kinase
- JNK:
-
c-Jun N-terminal kinase
- MAPK:
-
mitogen-activated protein kinase
- MEKK-1:
-
mitogen-activated protein kinase kinase kinase-1
- PAI-1:
-
plasminogen activator inhibitor type 1
- R-Smads:
-
receptor-regulated Smads
- SAPK:
-
stress-activated protein kinase
- TAK1:
-
TGF-β-activated kinase 1
- TβRI:
-
TGF-β type I receptor
References
Brown JD, DiChiara MR, Anderson KR, Gimbrone Jr MA and Topper JN . (1999). J. Biol. Chem., 274, 8797–8805.
Davis RJ . (1993). J. Biol. Chem., 268, 14553–14556.
de Caestecker MP, Parks WT, Frank CJ, Castagnino P, Bottaro DP, Roberts AB and Lechleider RJ . (1998). Genes Dev., 12, 1587–1592.
Derynck R, Zhang Y and Feng XH . (1998). Cell, 95, 737–740.
Engel ME, McDonnell MA, Law BK and Moses HL . (1999). J. Biol. Chem., 274, 37413–37420.
Furukawa F, Matsuzaki K, Mori S, Tahashi Y, Yoshida K, Sugano Y, Yamagata H, Matsushita M, Seki T, Inagaki Y, Nishizawa M, Fujisawa J and Inoue K . (2003). Hepatology, 38, 879–889.
Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA and Castellino FJ . (2000). Cancer Res., 60, 5839–5847.
Hannon GJ and Beach D . (1994). Nature, 371, 257–261.
Heldin CH, Miyazono K and ten Dijke P . (1997). Nature, 390, 465–471.
Hill CS and Treisman R . (1995). Cell, 80, 199–211.
Hirashima Y, Kobayashi H, Suzuki M, Tanaka Y, Kanayama N and Terao T . (2003). J. Biol. Chem., 278, 26793–26802.
Hua X, Liu X, Ansari DO and Lodish HF . (1998). Genes Dev., 12, 3084–3095.
Jonk LJ, Itou S, Heldin CH, ten Dijke P and Kruijer W . (1998). J. Biol. Chem., 273, 21145–21152.
Kimelman D and Kirschner M . (1987). Cell, 51, 869–877.
Kobayashi I, Kawano S, Tsuji S, Matsui H, Nakama A, Sawaoka H, Masuda E, Takei Y, Nagano K, Fusamoto H, Ohno T, Fukutomi H and Kamada T . (1996). In Vitro Cell Dev. Biol. Anim., 32, 259–261.
Kretzschmar M, Doody J and Massagué J . (1997). Nature, 389, 618–622.
Kretzschmar M, Doody J, Timokhina I and Massagué J . (1999). Genes Dev., 13, 804–816.
Li J-M, Nichols MA, Chandrasekharan S, Xiong Y and Wang X-F . (1995). J. Biol. Chem., 270, 26750–26753.
Macías-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L and Wrana JL . (1996). Cell, 87, 1215–1224.
Massagué J . (1998). Annu. Rev. Biochem., 67, 753–791.
Matsuzaki K, Date M, Furukawa F, Tahashi Y, Matsushita M, Sakitani K, Yamashiki N, Seki T, Saito H, Nishizawa M, Fujisawa J and Inoue K . (2000). Cancer Res., 60, 1394–1402.
Mulder KM . (2000). Cytokine Growth Factor Rev., 11, 23–35.
Nakao A, Afrakhte M, Morén A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH and ten Dijke P . (1997). Nature, 389, 631–635.
Piek E, Ju WJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M, Deng C, Kucherlapati R, Bottinger EP and Roberts AB . (2001). J. Biol. Chem., 276, 19945–19953.
Roberts AB, Anzano MA, Lamb LC, Smith JM and Sporn MB . (1981). Proc. Natl. Acad. Sci. USA, 78, 5339–5343.
Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF and Sporn MB . (1985). Proc. Natl. Acad. Sci. USA, 82, 119–123.
Roberts AB and Sporn MB . (1990). Peptide Growth Factors and Their Receptors, Part I, Vol 95 Sporn MB and Roberts AB. (eds). Springer-Verlag: Berlin, pp. 419−472.
Robinson MJ and Cobb MH . (1997). Curr. Opin. Cell Biol., 9, 180–186.
Sano Y, Harada J, Tashiro S, Gotoh-Mandeville R, Maekawa T and Ishii S . (1999). J. Biol. Chem., 274, 8949–8957.
Schlessinger J . (2002). Cell, 110, 669–672.
Stoker M, Gherardi E, Perryman M and Gray J . (1987). Nature, 327, 239–242.
Wakefield LM and Roberts AB . (2002). Curr. Opin. Genet. Dev., 12, 22–29.
Wrana JL . (2000a). Cell, 100, 189–192.
Wrana JL . (2000b). Sci. STKE, 2000, RE1.
Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E and Matsumoto K . (1995). Science, 270, 2008–2011.
Zhang Y, Feng XH and Derynck R . (1998). Nature, 394, 909–913.
Zhang Y and Derynck R . (1999). Trends Cell Biol., 9, 274–279.
Acknowledgements
We would like to thank Dr R Derynck (University of California at San Francisco) and Dr S Ohno (Yokohama City University School of Medicine) for providing us with cDNAs encoding human Smad2 and Smad3 and with cDNA encoding dominant-negative form of MEKK-1, respectively. We are grateful to Dr X-F Wang (Duke University) and Drs P ten Dijke and C-H Heldin (Ludwig Institute for Cancer Research) for the generous gifts of p15P113-luc vector and (SBE)4-Luc vector, respectively. We also thank Dr AB Roberts (National Cancer Institute) for helpful discussions concerned with the study. This study was supported by a Grant-in-Aid for scientific research from the Ministry of Education, Science and Culture of Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mori, S., Matsuzaki, K., Yoshida, K. et al. TGF-β and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 23, 7416–7429 (2004). https://doi.org/10.1038/sj.onc.1207981
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207981
Keywords
This article is cited by
-
Specific Smad2/3 Linker Phosphorylation Indicates Esophageal Non-neoplastic and Neoplastic Stem-Like Cells and Neoplastic Development
Digestive Diseases and Sciences (2021)
-
Involvement of the JNK signaling in granular corneal dystrophy by modulating TGF-β-induced TGFBI expression and corneal fibroblast apoptosis
In Vitro Cellular & Developmental Biology - Animal (2020)
-
Regulation of tumor angiogenesis and mesenchymal–endothelial transition by p38α through TGF-β and JNK signaling
Nature Communications (2019)
-
Tryptophan metabolites kynurenine and serotonin regulate fibroblast activation and fibrosis
Cellular and Molecular Life Sciences (2018)
-
Retinoic acid promotes myogenesis in myoblasts by antagonizing transforming growth factor-beta signaling via C/EBPβ
Skeletal Muscle (2015)